drugset / Trial / NCT02911961
APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors
Phase 4
Withdrawn
Denver Health and Hospital Authority
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · collabRocky Mountain Poison and Drug Center · collabUniversity of Colorado, Denver · collab
Non-randomizedParallel-groupOpen-labelScreening
Summary
The objective of this study is to provide preliminary data to describe serum acetaminophen-cysteine protein adduct (APAP-CYS) concentrations following therapeutic doses of acetaminophen in the setting of non-acetaminophen induced liver injury. This study will utilize hepatic embolization as a model of hepatic injury.
Timeline
- Start
- 2021-08
- Primary completion
- 2021-08
- Completion
- 2021-08
Outcome
Outcome not reported
Stopped (Enrollment): “Due to lack of enrollment and organizational desire to focus recruitment efforts on other studies.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acetaminophen | Small molecule | 1 g | — |